Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Rating of “Hold” from Analysts

Akoya Biosciences, Inc. (NASDAQ:AKYA) has been given an average rating of “Hold” by the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.43.

Several equities research analysts have commented on AKYA shares. Canaccord Genuity Group lowered shares of Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price (down previously from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Finally, Craig Hallum cut Akoya Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $7.00 to $5.00 in a research note on Friday, November 15th.

Institutional Investors Weigh In On Akoya Biosciences

A number of large investors have recently bought and sold shares of AKYA. GSA Capital Partners LLP grew its position in shares of Akoya Biosciences by 87.4% in the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after purchasing an additional 144,903 shares during the last quarter. Barclays PLC boosted its stake in Akoya Biosciences by 320.9% during the 3rd quarter. Barclays PLC now owns 39,472 shares of the company’s stock valued at $107,000 after purchasing an additional 30,095 shares during the period. State Street Corp grew its holdings in Akoya Biosciences by 4.2% in the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after buying an additional 18,361 shares during the last quarter. SG Americas Securities LLC bought a new position in Akoya Biosciences in the 4th quarter worth approximately $28,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after buying an additional 9,429 shares during the last quarter. 79.42% of the stock is currently owned by institutional investors.

Akoya Biosciences Trading Up 0.6 %

NASDAQ AKYA opened at $3.23 on Friday. The firm has a market capitalization of $160.11 million, a PE ratio of -2.74 and a beta of 1.18. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31. The company has a 50-day simple moving average of $2.45 and a 200-day simple moving average of $2.58. The company has a debt-to-equity ratio of 5.62, a quick ratio of 1.85 and a current ratio of 2.75.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.